Asker Healthcare Group AB/Skr ASKER
1D1W1MYTD1Y5YMAX
Capital at risk
About Asker Healthcare Group AB
Asker Healthcare Group AB operates in the healthcare industry, focusing on providing medical supplies, services, and equipment primarily to healthcare institutions. The company is involved in the distribution and logistics of medical consumables and advanced medical technology products. Headquartered in Sweden, Asker Healthcare Group serves markets across Europe, leveraging its extensive network to cater to hospitals, care homes, and other healthcare service providers. The company emphasizes efficient supply chain management and aims to support healthcare professionals with reliable product accessibility and quality service, ensuring continuity in patient care.
- Ticker
- Skr ASKER
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 4,885
- Headquarters
- Danderyd, Sweden
- Website
- www.asker.com
ASKER Metrics
BasicAdvanced
kr 22B
30.30
kr 1.87
-
kr 0.39
0.69%
Price and volume
Market cap
kr 22B
52-week high
kr 95.56
52-week low
kr 56.20
Average daily volume
936K
Dividend rate
kr 0.39
Financial strength
Current ratio
1.305
Quick ratio
0.773
Long term debt to equity
0.71
Total debt to equity
0.923
Dividend payout ratio (TTM)
21.78%
Interest coverage (TTM)
8.77%
Profitability
EBITDA (TTM)
1,880
Gross margin (TTM)
41.32%
Net profit margin (TTM)
3.80%
Operating margin (TTM)
7.01%
Effective tax rate (TTM)
21.23%
Revenue per employee (TTM)
kr 3,690,000
Management effectiveness
Return on assets (TTM)
4.78%
Return on equity (TTM)
10.49%
Valuation
Price to earnings (TTM)
30.301
Price to revenue (TTM)
1.203
Price to book
3.11
Price to tangible book (TTM)
-7.11
Price to free cash flow (TTM)
21.774
Free cash flow yield (TTM)
4.59%
Free cash flow per share (TTM)
2.597
Dividend yield (TTM)
0.69%
Forward dividend yield
0.69%
Growth
Revenue change (TTM)
13.40%
Earnings per share change (TTM)
46.07%
Bulls say / Bears say
Q2 2026 showed strong operating momentum: revenue increased 18% year over year to SEK 4.686bn, adjusted EBITA rose 24% to SEK 471m, and the adjusted EBITA margin expanded to 10.0%. (Asker Healthcare Group)
The West and Central businesses are producing meaningful earnings leverage: H1 adjusted EBITA increased 32% in West and 52% in Central, with margins improving to 9.6% and 9.2%, respectively. (Nasdaq Nordic)
The pipeline continues to add complementary specialist platforms: recent acquisitions include Med Kjemi in Norwegian hospital laboratories, Ambercell in Baltic medtech supply-chain solutions, and Murray Surgical in Irish surgical distribution; each was described as margin-enhancing or margin-positive by Asker. (Asker Healthcare Group; Asker Healthcare Group; Asker Healthcare Group)
Growth is becoming increasingly acquisition-led: in H1 2026, Central revenue rose 29% with 28% from acquisitions, while West rose 14% with 13% from acquisitions, leaving limited organic contribution in key regions. (Nasdaq Nordic)
The acquisition strategy is cash-intensive and increases balance-sheet risk: H1 operating cash flow was SEK 511m versus SEK 522m spent on acquisitions, while total interest-bearing liabilities reached SEK 5.4bn and cash declined to SEK 777m. (Nasdaq Nordic)
M&A execution and regulatory risk remain material: Asker discontinued the Kirstine Hardam transaction after a prolonged closing process, while its Ambercell acquisition was still subject to regulatory approval as of August 19, 2026. (Asker Healthcare Group; Asker Healthcare Group)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
Upcoming events
No upcoming events
Funds containing ASKER
AllEURGBPUSD
Fund name | Fund size | Skr ASKER weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.08% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.08% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.